Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study

Christina Brinkmann, Mohamed Abdel-Wahab, Francesco Bedogni, Oliver D. Bhadra, Gaetan Charbonnier, Lenard Conradi, David Hildick-Smith, Faraj Kargoli, Azeem Latib, Nicolas M. Van Mieghem, Mizuki Miura, Darren Mylotte, Uri Landes, Thomas Pilgrim, Friedrich Christian Riess, Maurizio Taramasso, Didier Tchétché, Luca Testa, Holger Thiele, John WebbStephan Windecker, Julian Witt, Peter Wohlmuth, Alexander Wolf, Joachim Schofer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


Objectives: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). Background: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing. Methods: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers. Results: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients. Conclusions: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.

Original languageEnglish
Pages (from-to)756-764
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Issue number4
Early online date15 May 2021
Publication statusPublished - Oct 2021

Bibliographical note

Funding Information:
John Webb: Consultant and receives research funding from Edwards Lifesciences, Abbott, Boston Scientific.

Funding Information:
Nicolas M. Van Mieghem: receives research grant support from Abbott, BostonScientific, Edwards, Medtronic, PulseCath BV, Daiichi Sankyo and Advisory fee from Abbott, BostonScientific, Abiomed, Medtronic, PulseCath BV, Daiichi Sankyo.

Funding Information:
Luca Testa: Medical Proctor for Boston Scientific, Meril, Concept Medical, ABBOTT, Philips and Advisory board member and/or Speaker fees and/or Institutional Research Grant from: BSCI, PHILIPS, ABBOTT, MEDTRONIC, TERUMO, Concept Medical.

Publisher Copyright:
© 2021 Wiley Periodicals LLC.


Dive into the research topics of 'Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study'. Together they form a unique fingerprint.

Cite this